CellVax Therapeutics Inc.
October 18, 2023
Company Description: CellVax Therapeutics is a privately-held clinical-stage company active in research, development, and innovation on human immunodiagnostic and autologous anticancer vaccines, developing proprietary cell-based cancer immunotherapy. The company's lead product, FK-PC101, is an ant-cancer vaccine for prostate cancer patients with a higher risk of recurrence after prostatectomy. FK-PC101 is based on the proprietary novel technology using the patient's own cancer cells to create specific tumor-presenting cells (TPC).
CEO/Top Company Official
Fernando Kreutz, Phd
Lead Product in Development
FK-PC101 is a product consisting of autologous human prostate cancer cells which have been modified to express MHC II on their surface by ex vivo incubation with hIFN-γ. Once the cancer cells have been modified to express MHC II, they are rendered immunogenic by cultivating the MHC II-expressing cells with a non-self antigen. During culture, the non-self antigen will be pinocytosed by the cancer cells, processed, and finally presented on the cell surface in the context of MHC II. Upon injection of the cells into the subject from whom they were originally isolated, the modified cancer cells will not only present a cancer neoantigen in the context of MHC I to naïve (unprimed) CD8+ cytotoxic T cells; but also present the non-self antigen (bovine origin) to CD4+ helper T cells in the context of MHC II. Further, when MHC II presents non-self antigen to the CD4+ helper T cells it will trigger the release of cytokines which have co-stimulating properties and will induce an immune response. Hence, the modified cancer cells have a dual mode of action, capable of activating both CD8+ cytotoxic T cells and CD4+ helper T cells, resulting in a strong and specific anti-cancer immune response.
Development Phase of Primary Product
Number Of Unlicensed Products